| [1] |
Ohashi K, Murakami Y, Murayama M. Four cases of mucin producing cancer of the pancreas on specific findings of papilla of vater[J]. Prog Dig Endosc, 1982(20):348-351.
|
| [2] |
Tanaka M，Chari S，Adsay V，et al. International consensus guidelines for management of intraductal papillary mucinous neoplasms and mucinous cystic neoplasms of the pancreas[J]. Pancreatology, 2006, 6(1/2):17-32.
|
| [3] |
Chang YR，Park JK，Jang JY，et al. Incidental pancreatic cystic neoplasms in an asymptomatic healthy population of21 745 individuals: large-scale，single-center cohort study[J]. Medicine, 2016, 95(51):e5535.
|
| [4] |
Zerboni G，Signoretti M，Crippa S, et al. Systematic review and meta-analysis: prevalence of incidentally detected pancreatic cystic lesions in asymptomatic individuals[J]. Pancreatology, 2019, 19(1):2-9.
|
| [5] |
中华外科青年医师学术研究社胰腺外科研究组. 中国胰腺囊性肿瘤外科诊治现状分析: 2 251例报告[J]. 中华外科杂志，2018，56(1):24-29.
|
| [6] |
Nagtegaal ID, Odze RD, Klimstra D, et al. The 2019 WHO classification of tumours of the digestive system[J]. Histopathology, 2020, 76(2):182-188.
|
| [7] |
Tanaka M, Fernández-Del Castillo C, Kamisawa T, et al. Revisions of international consensus Fukuoka guidelines for the management of IPMN of the pancreas[J]. Pancreatology, 2017, 17(5):738-753.
|
| [8] |
中华医学会外科学分会胰腺外科学组. 胰腺囊性疾病诊治指南(2015版)[J]. 临床肝胆病杂志, 2015, 31(9):1375-1378.
|
| [9] |
European Study Group on Cystic Tumours of the Pancreas. European evidence-based guidelines on pancreatic cystic neoplasms[J]. Gut, 2018, 67(5):789-804.
|
| [10] |
Gemenetzis G, Bagante F, Griffin JF, et al. Neutrophil-to-lymphocyte ratio is a predictive marker for invasive malignancy in intraductal papillary mucinous neoplasms of the pancreas[J]. Ann Surg, 2017, 266(2):339-345.
|
| [11] |
Hao S, Takahashi C, Snyder RA, et al. Stratifying intraductal papillary mucinous neoplasms by cyst fluid analysis: present and future[J]. Int J Mol Sci, 2020, 21(3):1147.
|
| [12] |
Springer S, Masica DL, Dal Molin M, et al. A multimodality test to guide the management of patients with a pancreatic cyst[J]. Sci Transl Med, 2019, 11(501):eaav4772.
|
| [13] |
Lee JH, Kim Y, Choi JW，et al. KRAS, GNAS, and RNF43 mutations in intraductal papillary mucinous neoplasm of the pancreas: a meta-analysis[J]. Springerplus, 2016, 5(1):1172.
|
| [14] |
Gaujoux S, Parvanescu A, Cesaretti M，et al. GNAs but not extended RAS mutations spectrum are associated with a better prognosis in intraductal pancreatic mucinous neoplasms[J]. Ann Surg Oncol, 2019, 26(8):2640-2650.
|
| [15] |
Wang J, Paris PL, Chen J，et al. Next generation sequencing of pancreatic cyst fluid microRNAs from low grade-benign and high grade-invasive lesions[J]. Cancer Lett, 2015, 356(2 Pt B):404-409.
|
| [16] |
Kuratomi N, Takano S, Fukasawa M, et al. MiR-10a in pancreatic juice as a biomarker for invasive intraductal papillary mucinous neoplasm by miRNA sequencing[J]. Int J Mol Sci, 2021, 22(6):3221.
|
| [17] |
Vege SS, Ziring B, Jain R, et al. American gastroenterological association institute guideline on the diagnosis and management of asymptomatic neoplastic pancreatic cysts[J]. Gastroenterology, 2015, 148(4):819-822.
|
| [18] |
Kadiyala V, Lee LS. Endosonography in the diagnosis and management of pancreatic cysts[J]. World J Gastrointest Endosc, 2015, 7(3):213-223.
|
| [19] |
Fernández-del Castillo C，Adsay NV. Intraductal papillary mucinous neoplasms of the pancreas[J]. Gastroenterology, 2010, 139(3):708-713, e1-2.
|
| [20] |
Park JK, Song BJ, Ryu JK, et al. Clinical outcomes of endoscopic ultrasonography-guided pancreatic cyst ablation[J]. Pancreas, 2016, 45(6):889-894.
|